Loading clinical trials...
Loading clinical trials...
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Supernus Pharmaceuticals, Inc.
NCT06810180 · Attention Deficit Hyperactivity Disorder (ADHD), Sleep, and more
NCT07189442 · Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
NCT07180758 · Attention Deficit Hyperactivity Disorder (ADHD)
NCT07459699 · Attention Deficit Hyperactivity Disorder (ADHD)
NCT04943796 · Attention Deficit Hyperactivity Disorder (ADHD)
Metropolitan Neuro Behavioral Institute
Chandler, Arizona
Woodland International Research Group
Little Rock, Arkansas
Sun Valley Research Center
Imperial, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions